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review” for publication in Cancer Treatment Reviews. 
 
The management of locally advanced rectal cancer is an evolving clinical field where the multidisciplinary 
approach can reach its best and liquid biopsy for obtaining tumor-derived component such as circulating tumor DNA 
(ctDNA) might provide important complementary pieces of information. While there are many reviews available in the 
literature concerning the broad applications of liquid biopsy in cancer treatment, including a few about colorectal 
cancer as a whole, no systematic review has been performed with the focus of this specific tumor type, that has 
distinctive clinical features and different treatment modalities as compared to colon cancer.  
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Abstract 20 
Background: The management of locally advanced rectal cancer (RC) is an evolving 21 
clinical field where the multidisciplinary approach can reach its best and liquid biopsy for 22 
obtaining tumor-derived component such as circulating tumor DNA (ctDNA) might provide 23 
complementary informations. 24 
 25 
Methods: A systematic review of studies available in literature of liquid biopsy in non-26 
metastatic RC has been performed according to PRISMA criteria to assess the role of 27 
ctDNA as a diagnostic, predictive and prognostic biomarker in this setting. 28 
 29 
Results: Twenty-five publications have been retrieved, of which 8 full-text articles, 7 30 
abstracts and 10 clinical trials. Results have been categorized into three groups: 31 
diagnostic, predictive and prognostic. Few but promising data are available about the use 32 
of liquid biopsy for early diagnosis of RC, with the main limitation of sensitivity due to low 33 
concentrations of ctDNA in this setting. In terms of prediction of response to 34 
chemoradiation, still inconclusive data are available about the utility of a pre-treatment 35 
liquid biopsy, whereas some studies report a positive correlation with a dynamic (pre/post-36 
treatment) monitoring. The presence of minimal residual disease by ctDNA was 37 
consistently associated with worse prognosis across studies. 38 
 39 
Conclusions: The use of liquid biopsy for monitoring response to chemoradiation and 40 
assess the risk of disease recurrence are the most advanced potential applications for 41 
liquid biopsy in RC, with implications also in the context of non-operative management 42 
strategies. 43 
 44 
Key Words: rectal cancer, liquid biopsy, ctDNA, non-operative management 45 
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BACKGROUND  46 
Colorectal cancer (CRC) is one of the most diagnosed cancers worldwide, with 1.84 million 47 
estimated new cases in 2018 [1]. About 25-30% of all colorectal cancer diagnoses 48 
accounts for rectal cancer (RC) [2]. In the European Union, the incidence of RC is 49 
~125000 per year, i.e. ~35% of the total colorectal cancer incidence, reflecting 15–25 50 
cases/100 000 population per year and is predicted to further increase in both genders. 51 
The mortality is 4–10/100 000 population per year, with a median age at diagnosis of ~70 52 
years [3]. 53 
The rectum and colon have a different embryological origin, anatomy and function [4]. RC 54 
has thus distinctive clinical features as compared to colon cancer, with an increased risk of 55 
local spread and recurrence. As a consequence, the treatments for primary rectal and 56 
colon cancer are different [5]. The incidence of RC has been decreasing as the 57 
increasingly spread use of screening allows for identification and endoscopic removal of 58 
premalignant lesions [6]; however, several recent studies have shown an increase in 59 
incidence of rectal cancers among young people [7]. 60 
The treatment landscape in RC paralleled that of colon cancer and has evolved over the 61 
last decade following the approval of several targeted therapies for the advanced disease, 62 
leading to improvements in tumor response rates and patient survival [8,9]. However, 63 
progresses in medical treatment in the metastatic setting have been mainly incremental 64 
despite considerable advances in the knowledge of tumor biology [10]. In this regard, 65 
primary tumor location (right-sided or left-sided of the colorectum) has been identified as a 66 
surrogate marker for underlying molecular classification, with differences in a continuum 67 
spectrum between colon and rectal carcinomas [11].  68 
In the non-metastatic setting, operative approaches such as transanal endoscopic 69 
microsurgery, open and laparoscopic proctectomy [12] are effective in earlier stages, while 70 
a trimodality treatment (pre-operative chemoradiation therapy (CRT), surgery with total 71 
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mesorectal excision (TME) followed by adjuvant chemotherapy) is the standard of care for 72 
locally advanced RC patients. A significant risk of distal recurrence is present in rectal 73 
tumors radically operated in particular within the first 5 years for stages II and III of Dukes 74 
at around 30% and 50%, respectively, probably caused by the presence 75 
of micrometastatic spread [6]. A pooled analysis of five European randomized controlled 76 
trials demonstrated that the 5-year distant metastasis rate was 30.8% in 2.759 recruited 77 
patients [3]. An increasing number of reports suggested that a non-operative management 78 
(NOM), consisting of close surveillance of patients with clinical complete response (cCR) 79 
after chemoradiotherapy, could be an acceptable alternative to rectal surgery 80 
(proctectomy). Led by small prospective series published since the late 90’s by Habr-81 
Gama and colleagues [13,14], several international series have reported similar oncologic 82 
outcomes in cCR patients followed by close active surveillance (the so-called watch-and-83 
wait (W&W) or NOM approach) compared to those treated with radical surgery [15,16]. 84 
More recently, the International Watch & Wait Database (IWWD) described the outcome of 85 
the W&W strategy in a large-scale registry of more than 1000 patients, reporting excellent 86 
survival and small risk of local unsalvageable disease recurrence [17]. Despite the body of 87 
retrospective literature is greatly increasing,  key knowledge gaps limiting widespread use 88 
of W&W/NOM remain, and clinical studies aimed at identifying patients who are good 89 
candidates for this approach are ongoing [18].  90 
Follow-up supported by clinical examinations, imaging and endoscopies aims to improve 91 
prognosis by early detection of local or distant recurrence. Isolated carcinoembryonic 92 
antigen (CEA) monitoring is insufficiently sensitive. The analysis of serum protein levels, 93 
such as CEA, allows a fast and cost-effective method to quantify cancer progress, but it’s 94 
distorted by limited sensitivity and specificity, in particular during treatment courses due to 95 
inflammation and discharge of protein in the bloodstream. Moreover, a portion of patients 96 
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with metastatic RC does not show visible plasmatic CEA levels during the disease 97 
[19,20].   98 
The management of RC is an evolving clinical field where the multidisciplinary approach 99 
can reach its best and the ability to discern patients at low risk from those at high risk of 100 
recurrence is the prerequisite for the most appropriate treatment choice. With this regard, 101 
liquid biopsy for obtaining tumor-derived component such as circulating tumor DNA 102 
(ctDNA) or circulating tumor cells (CTCs) might provide crucial complementary information 103 
at the diagnosis of RC and in different moments during its treatment. Liquid biopsies may 104 
indeed represent a precious basin of new generation biomarkers [21,22] and are being 105 
evaluated also in RC for diagnosis, treatment choice, monitoring disease response, 106 
tracking acquired mutations linked to targeted therapy resistance, and detecting minimal 107 
residual disease. 108 
The aim of this systematic review is to assess the role of ctDNA as a diagnostic, predictive 109 
and prognostic biomarker in non-metastatic RC.  110 
 111 
METHODS  112 
 113 
Definition of the Outcome  114 
The purpose is to evaluate the current clinical potential of liquid biopsy, in particular cell-115 
free DNA (cfDNA)/ circulating tumor DNA (ctDNA), in non-metastatic RC patients.  116 
 117 
Data Source and Search Strategy  118 
A systematic literature review was performed according to PRISMA Statement Criteria 119 
[23,24] in June 2019. The PubMed database was systematically reviewed as of June 11th, 120 
2019 and all retrieved studies were manually screened for relevant references missed in 121 
the primary search. Unpublished data presented as abstract in relevant international 122 
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congresses [American Society of Clinical Oncology (ASCO), European Society of Medical 123 
Oncology (ESMO)] were also systematically searched for. Furthermore, ongoing clinical 124 
trial exploring the value of liquid biopsy in non-metastatic rectal cancer were searched on 125 
clinicaltrial.gov. The decision to include a study for review was made by consensus 126 
between two authors (EGP and DM). The research criteria were limited to human studies 127 
published only in English language. The Medical Subject Heading terms used for the 128 
search were (“rectal” or “rectum” or “LARC”) and (“liquid biopsy” or “ctDNA” or “cfDNA” or 129 
“circulating tumor DNA” or “circulating free DNA” or “methylated DNA” or “DNA 130 
methylation”).  131 
Main study inclusion criteria: 132 
 Involved the measurement of cfDNA/ctDNA in plasma/serum in patients with RC; 133 
 Diagnosis, treatment response and/or survival data collected and correlated with 134 
cf/ctDNA. 135 
Study exclusion criteria: 136 
 Involved patients with metastatic RC; 137 
 Involved patients with CRC without mention about the tumor location. 138 
 139 
RESULTS 140 
A total of 838 records were screened to be included in the systematic review (Figure 1). 141 
We identified 8 records found through database searching (PUBMED) and 17 additional 142 
records identified through other sources (ESMO, ASCO, Clinicaltrial.gov).  143 
As a result, 26 records were eligible and included in the systematic review: 8 full-text 144 
articles studies, 7 abstracts presented at international congresses, and 10 ongoing ctDNA 145 
clinical trials.  146 
We subdivided our results into 3 categories according to the investigated role of 147 
ctDNA/cfDNA or methylated DNA: diagnostic, predictive of treatment response and 148 
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prognostic (in terms of disease recurrence or survival) (Figure 2). Finally, we provide a 149 
summary of published or presented works (Table 1) and of ongoing trials (Table 2). 150 
 151 
cfDNA and ctDNA as diagnostic tool 152 
In 2011 an Italian group evaluated the ability of cfDNA to discriminate healthy patients 153 
(plasma samples collected after a negative colonoscopy) from patients with RC. Through 154 
quantitative PCR (using Alu 115, Alu 147 and β-globin gene), they found that the baseline 155 
level of cfDNA was significantly higher in RC patients than in healthy individuals [25].  156 
A Chinese group also observed higher concentration of cfDNA in RC than in healthy 157 
individuals, where mutated KRAS and methylated MGMT were not detected. Moreover, 158 
the ratio of 400-/100-bp DNA fragments (an index of cfDNA integrity) was higher in RC 159 
patients than in healthy controls, in which cfDNA is considered to originate mainly from 160 
apoptotic process of normal cells [26].  161 
Shalaby et al. highlighted the capacity of MGMT and ERCC1 methylation status to 162 
distinguish benign and malignant rectal tumors. The study was performed in blood and 163 
tissue of 43 benign and 50 malignant rectal tumors patients. They observed a significant 164 
higher frequency of MGMT and ERCC1 methylation in RC patients than in cases with 165 
benign tumors, both in tissue and blood samples (sensitivity around 60% and specificity of 166 
93-95% for each gene on plasma). The combination of MGMT and ERCC1 methylation 167 
reached a specificity for differentiation between benign and malignant rectum tumor of 168 
100% in blood samples, with a sensitivity of 32% [27]. 169 
More recently, Zhang et al. observed that both colon and RC could be detected by ctDNA, 170 
with the latter having lower median plasma cfDNA concentrations in plasma than colon 171 
cancer patients (14.2 ng/ml vs. 8.94 ng/ml). The study was conducted on 29 patients, 172 
including 10 with RC. For each patient, a freshly frozen tissue sample was collected during 173 
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surgery and the plasma obtained was analyzed using an 85-gene panel, with a mutation 174 
concordance rate between ctDNA and tissue of 70% in all patients, lower in the subgroup 175 
of RC patients (5/10, 50%) [28].  176 
At the present time, one clinical trial is exploring the feasibility of ctDNA as a detection 177 
index for RC (Table 2). 178 
 179 
cfDNA and ctDNA as tool to predict treatment response  180 
Different groups analyzed the role of cf/ctDNA as a tool to monitor treatment response 181 
after CRT in locally-advanced rectal cancer (LARC). In 2008, Zitt and colleagues [29] 182 
observed for the first time a correlation between the concentration of cfDNA and clinical 183 
response after surgery (not after neoadjuvant CRT) in 26 patients: responders exhibited a 184 
reduction in cfDNA level, while non-responders showed an incremented cfDNA [29].    185 
Agostini et al. analyzed cfDNA on 67 LARC patients before and after neoadjuvant CRT, 186 
before surgery. Levels of longer fragments of cfDNA were reduced in responsive patients 187 
(tumor regression grade (TRG) 1-2, according to the Mandard score) compared to non-188 
responsive (TRG 3-5). In particular the post-CRT cfDNA integrity (the ratio of 400-/100-bp 189 
DNA fragments) was associated with response (P = 0.0009), confirming that cfDNA long 190 
fragments are more tumor-specific than short fragments. Baseline levels of cfDNA were 191 
not correlated with tumor response [25].  192 
The relationship between cfDNA concentration and TRG score was also observed by a 193 
Chinese group who focused also on different aspects of cfDNA: the 400-/100-bp ratio of 194 
DNA fragments, the methylation status of MGMT and the mutational status of KRAS. They 195 
treated 34 LARC patients with CRT followed by surgery. The good response group of 196 
patients had a significantly higher baseline 400-bp plasma cfDNA levels and showed a 197 
significant decrease of these fragments in plasma after CRT. On the contrary, no 198 
difference was observed regard the level of 100-bp fragments before and after CRT both 199 
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in responders and non-responders. In addition, the rate of MGMT promoter methylation at 200 
baseline was higher in responders, with no reduction after treatment, while the rate of 201 
KRAS mutation decreased in both groups after CRT [26]. 202 
Shalaby et al. described the same correlation between methylated status of the promoter 203 
of MGMT and ERCC1 genes with response to CRT. A higher methylation status was 204 
associated with a better tumor response after preoperative CRT [27]. 205 
A Danish group quantified the total level of cfDNA by fluorescence assay, using 40 μL of 206 
plasma of 123 LARC patients. They observed no differences either between baseline and 207 
post-treatment (CRT preceded by induction chemotherapy in 42% of cases) levels of 208 
cfDNA or between patients achieved a pathological complete response (pCR) and poor 209 
responders [30]. 210 
Carpinetti et al. firstly observed a decrease in ctDNA (detected due to tumor-specific 211 
chromosomal rearrangements) in 4 patients that achieved a response to CRT. By the way, 212 
cfDNA was negative both in patients with partial and complete pathological response [31].  213 
Tie et al. analyzed tissue and multiple plasma samples of 159 LARC patients treated with 214 
neoadjuvant CRT through next generation sequencing (NGS). ctDNA was detectable in 215 
77% of plasma samples before treatment, 8% during CRT and 12% at a postoperative 216 
stage. Detectable ctDNA after surgery was associated with known high risk pathological 217 
features (i.e. ypT3-4, node positive), but there was no statistically meaningful association 218 
between reduction or negativization of ctDNA after CRT and pCR [32]. 219 
Li et al. observed in a small study of 30 patients that ctDNA level variations (somatic 220 
mutations identified by NGS of 61-gene panels) can predict pathological response to 221 
neoadjuvant CRT, better than classic markers as CEA or CA 19.9 [33].  222 
McDuff et al. reported a higher rate of R0-node negative resections after CRT among 17 223 
patients with undetectable preoperative ctDNA, compared to 10 patients with detectable 224 
ctDNA. The former group had a higher pCR rate (24% vs. 10%) [34]. 225 
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Chen et al. identified ctDNA analyzing the methylation status of BCAT1 or IKZF1 gene 226 
through qPCR assay in 9 LARC patients. Five patients showed positivity for one or both of 227 
methylated genes before CRT, four of them exhibited a decrease in detection after 228 
treatment, consistent with partial or complete responses [35]. 229 
Two Chinese prospective cohort studies, presented at 2019 ASCO meeting, recruited 180 230 
LARC patients, overall, with serial plasma collection analyzed through NGS gene panels to 231 
detect mutations in ctDNA [36,37]. Yang et al. reported a negative correlation between 232 
presence of TP53 and APC gene in pre-treatment samples and response to nCRT, and 233 
detectability of pre-treatment mutations during nCRT significantly decreased from TRG3 to 234 
TRG0 group [37]. Zhou et al. observed a significant predictive role of pre-surgery ctDNA 235 
levels, where its persistency was linked with pathological N+, while an undetectable 236 
preoperative ctDNA correlated with pathological downstaging [36]. 237 
At the present time, six clinical trials are exploring the possibility to use ctDNA as a 238 
predictive tool (Table 2). 239 
 240 
cfDNA and ctDNA as a prognostic tool for disease recurrence or survival 241 
In a Danish study of 123 LARC patients, a solid association of baseline cfDNA level 242 
(measured through a fluorescence assay) with disease free survival (DFS) was found. 243 
High levels of cfDNA were correlated with higher risk of local or distant recurrence and 244 
with shorter time to recurrence. A non-statistically significative trend for overall survival 245 
(OS) was also observed [30].  246 
At a median follow up of 24 months, Tie and colleagues noticed an increased risk of 247 
recurrence in patients with ctDNA persistence after CRT or surgery. This risk of recurrence 248 
was irrespective either of pathological risk level (ypT3-4N+ vs ypT1-2N0 vs pCR) or of 249 
adjuvant therapy, with an estimate 3y RFS of 33% vs 87%. Post-operative ctDNA 250 
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detection was a stronger prognostic biomarker than CEA levels. Moreover, 74% of patients 251 
recurred within 12 months after surgery, 9/19 had persistent ctDNA in plasma [38]. 252 
As already said, Carpinetti et al, analysed in 4 LARC patients the use of ctDNA to monitor 253 
disease response and recurrence. Two patients with persistent positive level of ctDNA, 254 
during their follow up, developed liver metastasis concomitantly with an incremental in 255 
ctDNA level. Other 2 patients showed a drop in ctDNA levels after CRT, with negative 256 
follow up for recurrence and no more evidence of ctDNA in plasma [31].  257 
Four studies, presented at last ASCO and ESMO congresses, have explored the use of 258 
ctDNA as a tool to assess response and predict surgical outcome in LARC [34,35,39,40]. 259 
McDuff et al., among 22 patients treated with preoperative CRT, reported a shorter 260 
recurrence free survival in cases with detectable post-operative ctDNA [34]. Khakoo 261 
showed that persistence of ctDNA at mid CRT or detection of ctDNA at the end of CRT 262 
were associated with development of metastasis [40]. In the work presented by Chen, one 263 
patient that showed persistent high level of methylated genes after CRT, recurred in two 264 
months after surgery [35]. 265 
Conversely, in a study performed on 97 LARC patients receiving induction chemotherapy 266 
with CAPOX followed by CRT and then adjuvant CAPOX with or without cetuximab 267 
(EXPERT-C trial), Sclafani et al. did not found a significant association between ctDNA 268 
positivity/negativity and progression free survival (PFS) or OS using qPCR [41] . 269 
At the 2019 ASCO meeting, Yang et al. described a significant association between 270 
persistence of pre-treatment mutations in ctDNA after completion of CRT and worse DFS 271 
[37].  272 
Eight clinical trials are exploring the possibility to use cf/ctDNA as a prognostic tool (Table 273 
2). 274 
 275 
DISCUSSION  276 
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In present review several studies supported the use of liquid biopsy in RC as an 277 
innovative, minimally invasive procedure that could assist either the diagnostic-staging 278 
process and the assessment of treatment response. The limitations of data retrieved are 279 
mostly related to the relatively small sample size of the studies, heterogeneity of 280 
techniques used for liquid biopsy and timing of plasma samples (eg. after CRT or after 281 
surgery), and differences in treatment courses (e.g. induction chemotherapy or not) for 282 
patients with different stages of non-metastatic RC.   283 
We found 4 studies (overall 204 patients) which explored the role of liquid biopsy as a 284 
diagnostic tool in RC. Measurement of cfDNA levels was performed with different 285 
techniques: ALU-based quantitative-PCR, tracking mutations of KRAS, or, more recently, 286 
tracking of several gene with NGS and assessing the methylation status of MGMT and 287 
ERCC1 in ctDNA. These reports, although heterogeneous, suggest that measuring cfDNA 288 
levels or detecting ctDNA might discriminate RC patients from healthy controls and from 289 
individuals harbouring rectal adenoma. In particular, a high specificity in discriminating RC 290 
was reported for MGMT and ERCC1 methylation or KRAS mutation detection.  291 
These data are consistent with results obtained in colorectal cancer patients [42–44]. 292 
However, it should be taken into account  that in this setting of early detection of cancer, 293 
the sensibility of liquid biopsy is limited by low concentrations of circulating DNA in this 294 
setting, that have been reported to be even lower in RC [28].   295 
Contrasting data have been retrieved about the reliability of circulant DNA as a tool to 296 
predict treatment response in RC. The clinical value of baseline levels of cf/ctDNA is not 297 
clear. Only one small study showed a correlation between higher levels of longer cfDNA 298 
fragments (index of DNA integrity) and response [26], but these data were not consistent 299 
with results of a previous wider study [25]. Nevertheless, a strong methylation of MGMT or 300 
ERCC1 genes at baseline might better predict a tumor response after preoperative CRT 301 
[26,27]; on the contrary, detection of TP53 and APC gene in ctDNA of pre-treatment 302 
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samples has been negatively associated with response to CRT [37]. Notably, in a previous 303 
presentation of the same study, Yang et al. reported no difference in baseline ctDNA levels 304 
between responders and non-responders [39]. 305 
A noteworthy evidence, observed by most groups with different assays, consists in the 306 
reduction in cf/ctDNA levels in responders, while non-responders can show an 307 
incremented circulant DNA [25,26,29,31–33,35–37,45]. The timing of plasma collection 308 
represents a crucial aspect in this setting: at baseline, after induction chemotherapy, after 309 
neoadjuvant CRT, after surgery. Zitt et al. observed a reduction of DNA levels after CRT in 310 
all 26 patients but it was not predictive of pathological downstaging. A significant difference 311 
between responders and non-responders was found only in plasma samples collected 312 
after surgery [29]. 313 
In this same setting, a DNA integrity index (a ratio between long and short DNA fragments) 314 
has been proposed to be a useful guide to discriminate responding and non-responding 315 
patients even with plasma analysis conducted after neoadjuvant CRT [25,26].  316 
More recent studies, adopting NGS assays, have demonstrated the potential of post-CRT 317 
ctDNA samples to predict tumor response, enhancing the confidence in ctDNA as a tool to 318 
guide patient selection for watch and wait strategy. Different groups observed a correlation 319 
between undetectable preoperative ctDNA status and pathological downstage [33,36–320 
38,45]. A weaker methylation of BCAT1 or IKZF1 has been observed after CRT in good 321 
responders by Chen et al. [35].  322 
Finally, we found inconclusive data about the association between reduction or total 323 
clearance of circulant DNA after CRT and pCR. Likely, circulant DNA has no sufficient 324 
sensitivity to rule out the presence of minimal residual disease [38].  325 
In terms of survival and disease recurrence, almost all studies have shown a correlation 326 
between persistence of ctDNA after treatment and disease recurrence during follow up 327 
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[30,32,35–37,40,45]. One group also observed an association between high baseline 328 
cfDNA level and local or distant recurrence, with a trend for shorter OS [30].  329 
Tie et al., in a recent prospective study of LARC patient, detected ctDNA in 77%, 8,3% and 330 
12% of pretreatment, postchemoradiotherapy and post-surgery plasma samples, 331 
respectively. On the basis of ctDNA levels, they were able to stratify patients at very high 332 
risk of recurrence (ctDNA detectable after CRT (HR 6,6) or after surgery (HR 13,0)), 333 
estimating a 3-year recurrence-free survival of 33% vs 87% in positive/negative ctDNA 334 
patients. Postoperative ctDNA status remained an independent predictor of RFS 335 
irrespective of clinicopathological risk factor or adjuvant chemotherapy [38] 336 
These results are in line with the conclusions of studies conducted in the setting of 337 
resected colorectal cancer, where evidence of ctDNA after surgery or after adjuvant 338 
chemotherapy were linked with shorter recurrence-free survival [46,47].  339 
In contrast, among patients treated in the EXPERT-C trial (induction CAPOX, CRT, 340 
surgery, adjuvant CAPOX +/- cetuximab) a significant association between ctDNA 341 
positivity/negativity and PFS or OS was not observed. However, the plasma sample in this 342 
study was collected before surgery and all patients received both neoadjuvant and 343 
adjuvant chemotherapy [48].  344 
The potential role of liquid biopsy in RC is also currently being explored as translational 345 
endpoints in numerous clinical trials and can find an important application in the setting of 346 
NOM. The ongoing No-Cut study, a phase 2 clinical trial, will assess whether an 347 
oxaliplatin-enhanced neoadjuvant CRT, followed by an imaging-intensive, liquid biopsy-348 
enriched surveillance, can spare stage II-III rectal cancers from undergoing up-front 349 
demolitive radical surgery with a clinically acceptable rate of distant relapse. The 350 
translational component of the study could establish, by retrospective correlative analysis 351 
of contextual imaging and blood molecular findings, whether circulating mutated and/or 352 
15 
 
methylated tumoral DNA is a predictive marker for residual disease, and whether there is a 353 
correlation between ctDNA and cancer relapse (NCT03565029) (Figure 3). 354 
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Figure Legends 558 
Figure 1: Flow diagram representing the systematic review process performed according 559 
to PRISMA Statement. 560 
Figure 2: Euler-Venn diagram representing the results of our systematical research 561 
divided according to the role of ct/cf DNA  562 
Figure 3: Study design of NO-CUT trial and the potential role of liquid biopsy in non-563 
operative management of rectal cancer. 564 
Table 1: Studies exploring the role of liquid biopsy in non-metastatic rectal cancer 
* Only as an abstract  
	 	
Reference Year N. 
patients 
Country Assay Main findings 
Diagnostic 
Agostini et al. 2011 67 Italy qPCR cfDNA levels (using Alu 115, 247 and β 
globin gene) were higher in RC than in 
healthy group (P < 0.0001). 
Sun et al. 2014 34 China qPCR Concentrations of 100 bp and 400 bp 
fragments and the ratio of 400-/100-bp 
DNA were higher in RC than in healthy 
group (p<0.01).  
Mutated KRAS and methylated MGMT 
were not found in cfDNA of healthy 
controls. 
Shalaby et al. 2017 93 Egypt PCR MGMT or ERCC1 were methylated for 
4.7% and 7% in the blood of patients 
with benign lesions and for 58% and 
60% in RC patients (p < 0.001). 
Zhang et al.* 2019 10 China/USA NGS Mutation concordance rate among 
ctDNA and tissue was 50% in RC 
patients. 
Predict/Monitor Treatment Response 
Zitt. et al. 2008 26 Austria qPCR Post surgery cfDNA responders: 2.2 
ng/ml; cfDNA non responders:  5.1 
ng/ml (p = 0.006). 
Agostini et al. 2011 67 Italy qPCR Baseline cfDNA levels not correlated 
with tumor response.  
In responders, the median levels of Alu 
247 and the cfDNA integrity index (the 
ratio of 400-/100-bp DNA fragments) 
were significantly lower after CRT 
compared to baseline (p = 0.0048 and 
0.0005, respectively).  
Sun et al. 2014 34  China PCR The good response group had 
significantly higher baseline 400-bp 
DNA levels and DNA integrity index.  
Good response group had lower cfDNA 
integrity after CRT compared before 
CRT.  
MGMT promoter methylation at 
baseline was higher in responders, with 
no reduction after treatment, while the 
rate of KRAS mutation decreased in 
both groups after CRT. 
Shalaby et al. 2017 93 Egypt PCR Significant correlation between baseline 
MGMT and ERCC1 methylation and 
response to CRT. 
Schou et al. 2018 123 Denmark Fluorescence No differences in cfDNA levels between 
before and after CRT.  
Carpinetti et al. 2015 4 Brazil Whole 
genome 
sequencing 
ctDNA levels decreased in RC 
achieving response to CRT. 
Tie et al. 2018 159 Australia NGS No association between post-CRT 
ctDNA status and pCR.  
Postoperative ctDNA detection was 
associated with high-risk pathological 
factors such as ypT3-4 and ypN1-2 
stage. 
Table 1 
Li et al.* 1 2017 30 China NGS ctDNA predicts change in tumor burden 
better than CEA. 
McDuff et al.* 1 2019 31 USA NGS The rate of R0-NN resection was higher 
among pts with undetectable 
preoperative ctDNA compared to pts 
with a detectable ctDNA.  
Chen et al.* 1 2019 9 USA qPCR Methylated BCAT1 or IKZF1 genes 
were found in 5/9 patients.  
Correlation between decrease of 
methylation and partial/complete 
response. 
Zhou et al.* 1 2019 61 China NGS Correlation between undetectable 
preoperative ctDNA status and 
pathological downstage (p=0.02). 
Correlation between preoperative 
ctDNA positivity and the persistently 
involved lymph node (p = 0.02). 
Yang et al.* 1 2019 119 China NGS TP53 and APC gene in pre-treatment 
samples negatively correlated with 
response to nCRT. 
Detection of pre-treatment mutations in 
any time points during nCRT was 
significantly (P = 0.03) decreased from 
TRG3 to TRG0 group. 
Predicting disease recurrence 
Tie et al. 1 2018 159 Australia NGS Worse RFS if ctDNA was detectable 
after CRT or after surgery (estimated 3-
year recurrence-free survival was 33% 
for postoperative ctDNA-positive 
patients vs 87% for ctDNA-negative). 
Schou et al. 1 2018 123 Denmark Fluorescence High risk of recurrence pts with 
baseline cfDNA levels above 75th 
quartile (HR=2.48, 95% P=0.007).  
Carpinetti et al. 1 2015 4 Brazil Whole 
genome 
sequencing 
Changes of ctDNA levels after surgery 
predict tumour recurrence. 
McDuff et al* 1 2019 31 USA NGS Patients with detectable postoperative 
ctDNA had worse RFS. 
Khakoo et al.* 1 2018 47 UK Sequencing ctDNA level was higher in pts who 
showed metastases (64%) related to 
pts that did not (8.3% P = 0.0005).  
Chen et al.* 1 2019 9 USA qPCR Patients with high levels of 
methylated IKZF1 and BCAT1 in post-
treatment ctDNA recurred 2 months 
after surgery. 
Sclafani et al. 0 2018 97 UK ddPCR No difference in outcome between 
patients with or without detectable 
ctDNA after CRT. 
Yang et al.* 1 2019 119 China NGS Detection of pre-treatment mutations in 
ctDNA after completion of nCRT was 
significantly associated with worse 
DFS. 
 
cfDNA: circulating free DNA; RC: rectal cancer; ctDNA: circulating tumor DNA; CRT: chemoradiotherapy; pCR: pathologic complete response; NN: node 
negative; TRG: tumor regression grade; RFS: relapse-free survival; DFS: disease-free survival. 
 
Table 2. Ongoing studies investigating the role of cf/ct-DNA in non-metastatic rectal 
cancer. 
Study (Study ID) 
STATUS 
Location Phase Pts 
 
cf/ct DNA related outcomes 
 
Total Neoadjuvant Treatment Without Surgery 
For Locally Advanced Rectal Cancer: 
Prospective Clinical Trial To Assess Tumor 
Complete Response, Circulating Tumor 
Genetic And Epigenetic Biomarkers, And 
Stromal Transcriptome To Interpret Clinical 
Outcome (NO-CUT) 
(NCT03565029) 
Italy II 180 
PROGNOSTIC: local a/o relapse free 
survival 
 
Circulating Tumour DNA (ctDNA) Rectal 
Cancer and the Relationship to Extramural 
Venous Invasion  
(NCT02579278) 
UK 
Observational, 
Prospective 
 
40 
PREDICTIVE: presence or absence of 
ctDNA post CRT in EMVI-positive rectal 
cancer 
Application of Circulating Tumor DNA Test in 
the Diagnosis and Treatment of Patients With 
Advanced Rectal Cancer 
(NCT03615170) 
 
China 
Observational, 
Prospective 
 
200 
DIAGNOSTIC: explore the feasibility of 
ctDNA as a detection index for rectal cancer 
PREDICTIVE: evaluation of preoperative 
concurrent chemoradiotherapy, so as to 
provide guidance for subsequent treatment 
PROGNOSTIC: search for possible 
recurrence related mutations 
Observational Study on Rectal Cancer to Verify 
if Response After Chemo-radiotherapy Can be 
Predicted With a Particular Blood Test. 
(LiBReCa) 
(NCT03699410) 
Switzerlan
d 
Observational, 
Prospective 
 
35 
PREDICTIVE: negative prognostic value of 
ctDNA drawn from the mesenteric and 
peripheral blood to investigate if can predict 
the response after chemo-radiotherapy and 
before surgery 
A Study of the Role of Circulating Tumor DNA 
in Predicting the Likelihood of Organ 
Preservation After Clinical Complete Response 
to Neoadjuvant Therapy for Rectal Cancer 
(NCT03749083) 
USA 
Observational, 
Prospective 
 
55 PROGNOSTIC: local recurrence rate   
Investigation of the Value of ctDNA in 
Diagnosis, Treatment, and Surveillance of 
Surgically Resectable Colorectal Cancer – 
Cohorts for T1-2N0 rectal cancer who undergo 
local or radical resection  
(NCT03038217) 
China 
Observational, 
Prospective 
 
300 
PROGNOSTIC: disease free survival, local 
recurrence rate, overall survival 
 
MRI Simulation-guided Boost in Short-course 
Preoperative Radiotherapy for Unresectable 
Rectal Cancer (SUNRISE) 
(NCT03714490) 
China Phase II  200 
PREDICTIVE: predicting of treatment 
response  
PROGNOSTIC: survival  
Multicenter, Prospective, RCT：Investigation of 
Combined Modality Therapy for Locally 
Advanced Mid/Low Rect 
(NCT03042000) 
China 
Prospective, 
observational  
 
1200 
PREDICTIVE: predicting the therapeutic 
effects of NCRT 
PROGNOSTIC: disease free survival  
 
Totally Neoadjuvant FOLFOXIRI + Short-course 
Radiation + XELOX in Patients With Locally 
Advanced Rectal Cancer 
(NCT03484221) 
China Phase II  30 PROGNOSTIC: survival 
Preoperative Chemoradiotherapy With 
Raltitrexed for Intermediate or Locally 
Advanced Rectal Cancer in the Fit Elderly 
(NCT02992886) 
China Phase II   68 
PREDICTIVE: predictive treatment response 
PROGNOSTIC: disease free survival 
	
Table 2
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: 
The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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Graphical Abstract (for review)
 Liquid biopsy for obtaining tumor-derived component such as circulating tumor DNA 
(ctDNA) might be used as a biomarker for improving rectal cancer management 
 
 ctDNA is under study in rectal cancer as for diagnostic, predictive and prognostic utility 
 
 Monitoring response to chemoradiation and assessing the risk of disease recurrence are 
the most advanced potential applications for liquid biopsy in rectal cancer 
 
*Highlights (for review)
